We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


CEPI Announces Ninth COVID-19 Vaccine Development Partnership

CEPI Announces Ninth COVID-19 Vaccine Development Partnership content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 2 minutes

CEPI, the Coalition for Epidemic Preparedness Innovations, today announced a ninth worldwide collaboration to develop a COVID-19 vaccine. CEPI will invest an initial US$3.5 million in a partnering agreement with Clover Biopharmaceuticals AUS Pty Ltd (“Clover Australia”) a wholly-owned subsidiary of Sichuan Clover Biopharmaceuticals, Inc (China) (“Clover Biopharmaceuticals”), bringing the organisation’s total investment in COVID-19 vaccine research & development to US$39.6m.

This initial CEPI investment will support Clover Australia in its efforts to initiate a phase 1 clinical trial in Australia of its COVID-19 S-Trimer vaccine candidate. This innovative vaccine candidate is based on Clover Biopharmaceutical’s proprietary Trimer-Tag© vaccine technology platform, which is a novel way to produce the spike proteins of the COVID-19 virus in a native trimeric form for use in a vaccine. If successful in clinical trials, Clover Biopharmaceuticals has the capacity to rapidly scale up the production of the vaccine using its in-house biomanufacturing capabilities.

“We are delighted to partner with Clover Australia on their innovative COVID-19 S-Trimer vaccine candidate. They produced their vaccine within a month of the virus sequence becoming available, and they have rapidly advanced toward a first in human trial. This vaccine candidate is an important new addition to the CEPI portfolio. CEPI has invested in a diverse range of innovative vaccine platforms, as well as more established vaccine technologies, to maximise our chances of success as we pursue our ambition of making COVID-19 vaccines available for broad use." - Dr. Richard Hatchett, Chief Executive Officer, CEPI.

To date, CEPI has provided initial support and funding to Curevac, Inc., Inovio Pharmaceuticals, Inc., Moderna, Inc., Novavax, Inc., The University of Hong Kong, The University of Oxford, The University of Queensland and a consortium led by Institut Pasteur to develop COVID-19 vaccine candidates.

This investment is the result of a recent global call for proposals that CEPI issued in early February, which invited funding applications for vaccine technology that could be used to rapidly develop a vaccine against the new coronavirus, and most importantly at scale and with the necessary equitable access provisions.

CEPI recently officially announced that it has opened a Representative Office in Shanghai. Through its Shanghai Representative Office,CEPI will seek cooperation with China in the prevention and control of pandemic diseases, including funding of public health research projects, technical research and development of vaccines, and international scientific, technology and development cooperation and exchanges.

“At Clover Biopharmaceuticals, we are proud to receive CEPI’s funding and support for Clover Australia, which are critical to enabling the ongoing development and acceleration of our COVID-19 S-Trimer vaccine program that utilizes our innovative Trimer-Tag© platform technology. We have been working tirelessly and hope to contribute significantly to global efforts in fighting this pandemic that has affected us all." - Joshua Liang, Chief Strategy Officer of Clover Biopharmaceuticals and co-inventor of COVID-19 S-Trimer vaccine.

COVID-19 S-Trimer vaccine

Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. The trimeric S protein of SARS-CoV-2 is responsible for binding to host cell surface receptor ACE2 and subsequent viral entry, making it the primary target antigen for vaccine development. S-Trimer resembles the native trimeric viral spike protein and is produced via a rapid mammalian cell-culture based expression system.